The Fundraising Test: Diversification, Discipline, and Strategic Partnerships as the Durable Formula for Global Biotech Investing
In a frozen funding market, Frederick Shane argues that what still gets biotech funded isn’t perfect data—but disciplined leadership, credible risk reframing, and cross-border validation that proves a team can execute under pressure.
Biotech today faces a structural mismatch: breakthrough science is increasing, but capital is becoming harder, more selective, and more skeptical—especially across borders. Even late-stage companies with promising data are struggling to raise funding in a constrained financing environment, where investors are no longer persuaded by narratives alone.
Frederick Shane, Managing Partner at Axil Capital, argues that the deciding factors are no longer just technology or market size, but execution credibility under uncertainty. In practice, his investment lens focuses on two filters that rarely appear in pitch decks: how management teams frame scientific and business setbacks, and whether they can translate regional strengths into globally validated, investable strategies.
In Biotech, the Pitch Isn’t the Story—How You Answer Is
Shane’s investing lens starts with an observation familiar to anyone who has sat through diligence calls: nobody has a perfect product, and no company has perfect data. What matters is whether the management team can respond with clarity, logic, and credibility.
“You can’t expect a perfect product or a perfect answer anyway,” he said. “It’s how you answer that matters most of the time.”
He emphasized a style of communication that blends preparedness with brevity—“elevator pitch style,” as he put it. “You need to have a short answer, the right answer, and have it practiced and well done.”
In Shane’s framing, even bad results can be investable if management can explain what the failure revealed and how it opens a new path. “Even if your results were bad, it depends on whether you can actually put it in a constructive light,” he said—then offered the template investors respond to: “Yes, the experiments failed, but they gave us an opening to explore something new.”
What he kept coming back to was not optimism, but credible reframing. “It’s about reframing the risk into the reward,” he said. If a team can “verbalize that in a convincing manner,” they are “more than halfway there.”
When Setbacks Are the Real Diligence File
To illustrate what that looks like in reality, Shane pointed to a portfolio example where the company’s story was defined as much by endurance as by science. The details were less important than the pattern: scientific setbacks, business disruption, and external shocks that forced the team to keep operating when the normal playbook broke.
He described the period as “hard times”—not only in science, but in execution. “They persevered through a lot, not just because of the scientific setbacks, but also during COVID,” he said, recalling how a founder was “stuck for about six months.”
For Shane, these aren’t side stories. They are the proof points that don’t appear in slide decks. “You can never be sure what kind of management team has that or not,” he said. “We try to assess it, but that can be even more important than the technology or science in certain respects.”
Differentiation Is Hard in Crowded Categories—So Proof and People Matter More
Shane was direct about why leadership quality becomes decisive in immunology: it’s a space where claims are easy to make and hard to defend. “It’s difficult to differentiate because there are so many variants,” he said, describing how platform narratives can blur together at the level investors often hear them.
That means teams don’t win confidence with abstract positioning—they win it with substance and credibility. In his telling, what made the portfolio example compelling wasn’t a single “perfect” datapoint; it was that the company was “producing early results that were convincing enough,” paired with a founder who stayed “serious and focused.”
He also pointed to an “acceptance layer” that matters to cross-border capital: the ability to be understood and taken seriously by external scientific authorities. “He has been in touch with KOLs in the U.S. as well as Japan,” Shane noted, describing “acceptance from scientific authorities worldwide” alongside “acceptance from international investors as well.”
The Financing Environment Is the Backdrop—and It Changes Everything
Shane repeatedly returned to the current capital environment: even companies with credible programs are struggling. “Right now we’re in a very unique financing environment,” he said. “Even with a compelling late-stage product, companies are having a hard time raising capital.”
In that market, he argued, survival depends on execution creativity without narrative distortion. Teams need to be able to pivot without looking erratic—shifting strategy in ways that are legible to investors and grounded in external validation.
“You have to be able to pivot a few times,” he said. Sometimes that includes “a bit of serendipity,” but the discipline is the point: pivoting in a way that still feels like a coherent plan.
Axil Capital’s Strategy: Diversification as Risk Architecture
Where some funds build concentrated conviction, Shane positioned Axil’s strategy as portfolio architecture. “In a nutshell, our strategy is diversification,” he said—then laid out the framework: “We diversify across sub-segments and are indication agnostic.” They are also “stage-wise agnostic,” funding “very early stage and also pre-IPO,” and they are “geographically diversified.”
His reasoning was practical: cycles differ by market, and diversification is supposed to catch the spread. “Over the past few years, the U.S. market has been dead and frozen,” he said. “Japan’s market is not so bad, but Taiwan has been doing relatively well. Now Hong Kong is coming back.”
When one market stalls, another can carry momentum. “That’s where geographic diversification strategy is supposed to work,” he said. “If one is not doing great, another will pick it up. It’s about not putting all your eggs in one basket.”
The IPO Isn’t the Endgame—Partnership Is
As the conversation turned toward IPO readiness, Shane offered a blunt industry view: for many Asia-originating biotechs, the defining milestone isn’t simply listing—it’s landing a conspicuous partnership.
“I think partnership is the next big milestone,” he said. One “very visible partnership deal” can “elevate their status, drive their stock price,” and help a company “generate more products in the pipeline.”
His reasoning was structural: “It requires so much capital to develop early-stage assets,” he said. The biotech industry depends on the pharmaceutical industry for late-stage execution—trials, manufacturing, and marketing—because “Big Pharma cannot innovate on their own.”
That’s why partnership acts like validation infrastructure: it signals credibility, brings resources, and makes the next stage financeable.
Execution Hubs in Biotech: Quality, Cost Efficiency, and Globally Legible Talent
More broadly, Shane points to a pattern increasingly visible across Asia’s leading biotech ecosystems: the ability to deliver high-quality execution at a competitive cost base. He does not frame this as a single-market advantage, but as an operational layer that global investors evaluate when deciding where science can move efficiently from research into clinical and commercial milestones.
He stresses that regulatory environments in several Asian innovation hubs now support earlier-stage clinical development more actively, allowing startups to progress trials with greater speed and cost discipline. As he noted, authorities are “providing a conducive environment for earlier-stage startups to go through clinical trials,” underscoring that efficiency—not just access to capital—has become a key differentiator in a tighter financing cycle.
He also identifies talent as a globally relevant factor. Many research teams across Asia operate at internationally recognizable standards, with scientists trained at top institutions and experienced in cross-border collaboration. This produces what investors view as a globally legible workforce: operators who can engage seamlessly with KOLs, regulators, and partners across the U.S., Japan, and Europe without gaps in scientific rigor or communication.
For cross-border investors, the implication centers on execution credibility rather than geography. Markets that combine technical competence, cost efficiency, and internationally aligned talent pools increasingly act as translation hubs that bridge early discovery with global commercialization.
Cross-Border Collaboration: Trust, Alignment, and Operational Compatibility
Shane frames cross-border collaboration not as a trend, but as a function of operational compatibility and trust. Ecosystems that share similar regulatory philosophies, business cultures, and scientific standards collaborate more fluidly and reduce friction in partnerships, licensing, and joint development.
“When I come to Taiwan, the mindset is very similar to Japan,” he observed, pointing to how cultural and operational alignment simplifies cross-border business. More broadly, investors favor regions with an established track record of cooperation and mutual credibility rather than isolated, one-off collaborations.
He also emphasizes the role of trust infrastructure. Long-standing academic ties, established investor syndicates, and shared exposure to global regulatory standards create environments where partners can trust the quality of the technology, making partnerships more predictable and scalable.
Even as geopolitical dynamics shift, Shane identifies a stable collaboration corridor spanning the U.S., Japan, parts of Asia, and Western Europe that continues to support biotech investment and company building. In practice, cross-border scale depends less on novelty and more on aligned systems, proven relationships, and execution frameworks that global partners already recognize as credible.
Cross-Border Biotech Investing, in Five Hard-Learned Rules
Toward the end of the discussion, Shane distilled what he sees as practical rules for biotech founders raising from global investors—rules that are as much about relationship durability as they are about capital.
First: know what your investor actually wants. “Make sure you know their strategy and what they want,” he said. Investors come in different “sizes and shapes”—family offices, traditional VCs, passive funds, and hands-on investors. Fit matters because “it’s at least a 10-year relationship.”
Second: be honest and transparent. “Being honest is important. It’s okay not to have the best answer,” he said. There’s a difference between presenting in a good light and misleading. “Presenting something positively is different from using hyperbole,” he warned, because overselling “turns off investors.”
Third: adapt to culture. “There are cultural differences,” he said. With Japanese investors, “you don’t want to oversell.” His shorthand: “Know your client.”
Fourth: show insight, not just raw data. “If you just look at raw data, any PhD student can do that,” he said. What matters is whether you can “really analyze it and start to see different angles”—the kind of thinking that produces discoveries rather than checklist results.
Fifth: tenacity and curiosity are part of the asset. He tied execution back to character traits that show up under stress: patience, inquisitiveness, and the ability to keep learning. “Are you curious? Do you really want to do this?” he asked, describing how teams who stay engaged eventually begin to “enjoy the process and do it on their own.”
The Reality Check Behind Cross-Border Scale
Shane’s remarks offered a view of biotech investment that sits somewhere between finance and human judgment. Strategy matters—diversification, market cycles, and cross-border corridors of trust—but he repeatedly returned to a simpler test: whether the people building the company can carry the story when the story becomes difficult.
In a market where capital is scarce and attention is expensive, “scalable” is not just about platform technology. It is about execution credibility across borders: teams that can communicate with discipline, pivot without losing trust, and convert regional strengths—Taiwan’s cost-quality efficiency, Japan’s partnership depth, and U.S. market validation—into one coherent path forward.
In Shane’s framing, that is what makes cross-border biotech investable: not perfection, but the ability to keep moving when conditions stop cooperating.
Beyond the IPO, Frederick Shane (featured) argues that the real milestone in Asian biotech financing is securing a globally credible partnership that validates science, unlocks capital, and signals long-term execution strength. Image: GeneOnline
©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Taiwan’s Biotech Leaders Double Down on AI and US Manufacturing: Inside Bora and EirGenix’s Strategic Roadmaps
2026-02-03
From Main Venue Presentations to Strategic Partnering, Taiwan’s Biotech Sector Makes Its Mark in JPM 2026
2026-01-13
From Laboratory to Deal-making Table: Navigating Challenges in Global Business Development and Due Diligence
2025-11-25
